TP53 and neoplasm: A Caris Life Sciences molecular test performed on the prostate biopsy revealed a pathogenic TP53 mutation (p.C176Y), a tumor mutational burden (TMB) of 1 mutation per megabase, and low (3%) genomic loss of heterozygosity (gLOH).